Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Change in Account Payables (2020 - 2025)

Arcutis Biotherapeutics has reported Change in Account Payables over the past 6 years, most recently at $6.7 million for Q4 2025.

  • Quarterly results put Change in Account Payables at $6.7 million for Q4 2025, up 6510.48% from a year ago — trailing twelve months through Dec 2025 was -$1.7 million (down 176.0% YoY), and the annual figure for FY2025 was -$1.7 million, down 176.0%.
  • Change in Account Payables for Q4 2025 was $6.7 million at Arcutis Biotherapeutics, up from -$9.3 million in the prior quarter.
  • Over the last five years, Change in Account Payables for ARQT hit a ceiling of $6.7 million in Q4 2025 and a floor of -$9.3 million in Q3 2025.
  • Median Change in Account Payables over the past 5 years was $263000.0 (2022), compared with a mean of $274850.0.
  • Biggest five-year swings in Change in Account Payables: crashed 1931.34% in 2023 and later soared 6510.48% in 2025.
  • Arcutis Biotherapeutics' Change in Account Payables stood at $2.4 million in 2021, then crashed by 92.39% to $182000.0 in 2022, then plummeted by 755.49% to -$1.2 million in 2023, then skyrocketed by 91.2% to -$105000.0 in 2024, then soared by 6510.48% to $6.7 million in 2025.
  • The last three reported values for Change in Account Payables were $6.7 million (Q4 2025), -$9.3 million (Q3 2025), and $554000.0 (Q2 2025) per Business Quant data.